scholarly journals Differential Idiotype Utilization for the In Vivo Type 14 Capsular Polysaccharide-Specific Ig Responses to IntactStreptococcus pneumoniaeversus a Pneumococcal Conjugate Vaccine

2012 ◽  
Vol 189 (2) ◽  
pp. 575-586 ◽  
Author(s):  
Jesus Colino ◽  
Leah Duke ◽  
Swadhinya Arjunaraja ◽  
Quanyi Chen ◽  
Leyu Liu ◽  
...  
Keyword(s):  
Conjugate Vaccine ◽  
Pneumococcal Conjugate Vaccine ◽  
Capsular Polysaccharide

scholarly journals Should Pneumococcal Serotype 3 Be Included in Serotype-Specific Immunoassays?

Vaccines ◽  
2019 ◽  
Vol 7 (1) ◽  
pp. 4 ◽  
Author(s):  
Ezra Linley ◽  
Abigail Bell ◽  
Jenna F. Gritzfeld ◽  
Ray Borrow
Keyword(s):  
Conjugate Vaccine ◽  
Invasive Pneumococcal Disease ◽  
Pneumococcal Conjugate Vaccine ◽  
Pneumococcal Disease ◽  
Capsular Polysaccharide ◽  
Multiplex Assay ◽  
Limited Efficacy ◽  
The Future ◽  
Pneumococcal Serotype

Since the introduction of the 13-valent pneumococcal conjugate vaccine, a number of studies have demonstrated the limited efficacy of the pneumococcal serotype 3 component of this vaccine. Evidence from seven countries (Denmark, France, Greece, Portugal, Sweden, UK, US) shows limited or no effectiveness of the 13-valent pneumococcal conjugate vaccine against serotype 3 invasive pneumococcal disease and carriage. The serotype 3 capsule has some unique characteristics that may serve to explain this lack of efficacy—capsular polysaccharide is abundantly expressed, leading to a greater thickness of capsule, and free capsular polysaccharide may be released during growth. The serotype 3 component of the Luminex multiplex assay demonstrates inferior inter-laboratory reproducibility than other components and results may not be reliable. This communication outlines this evidence and discusses whether it is necessary to include serotype 3 in the assay in the future.

scholarly journals A stabilized glycomimetic conjugate vaccine inducing protective antibodies against Neisseria meningitidis serogroup A

2020 ◽  
Vol 11 (1) ◽  
Author(s):  
Jacopo Enotarpi ◽  
Marta Tontini ◽  
Cristiana Balocchi ◽  
Daan van der Es ◽  
Ludovic Auberger ◽  
...  
Keyword(s):  
Neisseria Meningitidis ◽  
Shelf Life ◽  
Conjugate Vaccine ◽  
Capsular Polysaccharide ◽  
Antibody Binding ◽  
Liquid Formulation ◽  
In Vivo Testing ◽  
Protective Antibodies ◽  
Polyclonal Serum

AbstractNeisseria meningitidis serogroup A capsular polysaccharide (MenA CPS) consists of (1 → 6)-2-acetamido-2-deoxy-α-D-mannopyranosyl phosphate repeating units, O-acetylated at position C3 or C4. Glycomimetics appear attractive to overcome the CPS intrinsic lability in physiological media, due to cleavage of the phosphodiester bridge, and to develop a stable vaccine with longer shelf life in liquid formulation. Here, we generate a series of non-acetylated carbaMenA oligomers which are proven more stable than the CPS. An octamer (DP8) inhibits the binding of a MenA specific bactericidal mAb and polyclonal serum to the CPS, and is selected for further in vivo testing. However, its CRM197 conjugate raises murine antibodies towards the non-acetylated CPS backbone, but not the natural acetylated form. Accordingly, random O-acetylation of the DP8 is performed, resulting in a structure (Ac-carbaMenA) showing improved inhibition of anti-MenA CPS antibody binding and, after conjugation to CRM197, eliciting anti-MenA protective murine antibodies, comparably to the vaccine benchmark.

scholarly journals Capsular Polysaccharide-Fimbrial Protein Conjugate Vaccine Protects against Porphyromonas gingivalis Infection in SCID Mice Reconstituted with Human Peripheral Blood Lymphocytes

1998 ◽  
Vol 66 (1) ◽  
pp. 391-393 ◽  
Author(s):  
Jeom-Il Choi ◽  
Robert E. Schifferle ◽  
Fuminobu Yoshimura ◽  
Byung-Woo Kim
Keyword(s):  
Conjugate Vaccine ◽  
Porphyromonas Gingivalis ◽  
Capsular Polysaccharide ◽  
Human Peripheral Blood ◽  
Peripheral Blood Lymphocytes ◽  
Scid Mice ◽  
Protein Conjugate ◽  
Periodontal Infection ◽  
Fimbrial Protein

ABSTRACT The effect of immunization with either a Porphyromonas gingivalis fimbrial protein, a capsular polysaccharide, or a capsular polysaccharide-fimbrial protein conjugate vaccine were compared in hu-PBL-SCID mice. A significantly higher human immunoglobulin G antibody response and the highest degree of in vivo protection against bacterial challenge was observed in the group immunized with the conjugate vaccine. It was concluded that capsular polysaccharide-fimbrial protein conjugate from P. gingivalis could potentially be developed as a vaccine against periodontal infection by P. gingivalis.

Humoral immune response of a pneumococcal conjugate vaccine: Capsular polysaccharide serotype 14—Lysine modified PspA

Vaccine ◽  
2011 ◽  
Vol 29 (47) ◽  
pp. 8689-8695 ◽  
Author(s):  
Raquel Santamaria ◽  
Cibelly Goulart ◽  
Catia T. Perciani ◽  
Giovana C. Barazzone ◽  
Rimenys Jr. Carvalho ◽  
...  
Keyword(s):  
Immune Response ◽  
Conjugate Vaccine ◽  
Humoral Immune Response ◽  
Pneumococcal Conjugate Vaccine ◽  
Capsular Polysaccharide ◽  
Humoral Immune

scholarly journals Protection against Streptococcus suis Serotype 2 Infection Using a Capsular Polysaccharide Glycoconjugate Vaccine

2016 ◽  
Vol 84 (7) ◽  
pp. 2059-2075 ◽  
Author(s):  
Guillaume Goyette-Desjardins ◽  
Cynthia Calzas ◽  
Tze Chieh Shiao ◽  
Axel Neubauer ◽  
Jennifer Kempker ◽  
...  
Keyword(s):  
Conjugate Vaccine ◽  
Functional Activity ◽  
Bacterial Infections ◽  
Capsular Polysaccharide ◽  
Streptococcus Suis ◽  
Vaccine Strategy ◽  
Content Type ◽  
Glycoconjugate Vaccine

Streptococcus suisserotype 2 is an encapsulated bacterium and one of the most important bacterial pathogens in the porcine industry. Despite decades of research for an efficient vaccine, none is currently available. Based on the success achieved with other encapsulated pathogens, a glycoconjugate vaccine strategy was selected to elicit opsonizing anti-capsular polysaccharide (anti-CPS) IgG antibodies. In this work, glycoconjugate prototypes were prepared by couplingS. suistype 2 CPS to tetanus toxoid, and the immunological features of the postconjugation preparations were evaluatedin vivo. In mice, experiments evaluating three different adjuvants showed that CpG oligodeoxyribonucleotide (ODN) induces very low levels of anti-CPS IgM antibodies, while the emulsifying adjuvants Stimune and TiterMax Gold both induced high levels of IgGs and IgM. Dose-response trials comparing free CPS with the conjugate vaccine showed that free CPS is nonimmunogenic independently of the dose used, while 25 μg of the conjugate preparation was optimal in inducing high levels of anti-CPS IgGs postboost. With an opsonophagocytosis assay using murine whole blood, sera from immunized mice showed functional activity. Finally, the conjugate vaccine showed immunogenicity and induced protection in a swine challenge model. When conjugated and administered with emulsifying adjuvants,S. suistype 2 CPS is able to induce potent IgM and isotype-switched IgGs in mice and pigs, yielding functional activityin vitroand protection against a lethal challengein vivo, all features of a T cell-dependent response. This study represents a proof of concept for the potential of glycoconjugate vaccines in veterinary medicine applications against invasive bacterial infections.

Sign in / Sign up

Export Citation Format

Share Document